Search Results - Querolt, Montse

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

    A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency by Santamaria, Manuel, Neth, Olaf, Douglass, Jo A., Krivan, Gergely, Kobbe, Robin, Bernatowska, Ewa, Grigoriadou, Sofia, Bethune, Claire, Chandra, Anita, Horneff, Gerd, Borte, Michael, Sonnenschein, Anja, Kralickova, Pavlina, Ramón, Silvia Sánchez, Langguth, Daman, Gonzalez-Granado, Luis Ignacio, Alsina, Laia, Querolt, Montse, Griffin, Rhonda, Hames, Carrie, Mondou, Elsa, Price, Jeffrey, Sanz, Ana, Lin, Jiang

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

    Correction to: A Multi-center, Open-Label, Single-Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodefic... by Santamaria, Manuel, Neth, Olaf, Douglass, Jo A., Krivan, Gergely, Kobbe, Robin, Bernatowska, Ewa, Grigoriadou, Sofia, Bethune, Claire, Chandra, Anita, Horneff, Gerd, Borte, Michael, Sonnenschein, Anja, Kralickova, Pavlina, Ramón, Silvia Sánchez, Langguth, Daman D., Gonzalez‑Granado, Luis Ignacio, Alsina, Laia, Querolt, Montse, Griffin, Rhonda, Hames, Carrie, Mondou, Elsa, Price, Jeffrey, Sanz, Ana, Lin, Jiang

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery

    A Phase 3, Randomized, Active-controlled, Single-blind Clinical Trial to Evaluate the Efficacy of Fibrin Sealant Grifols in Achieving Hemostasis in Pediatric Surgery by Balanescu, Laura, Gajdobranski, Djordje, Sretenović, Aleksandar, Kalinova, Krasimira, Vajda, Péter, Hanna, Kim, Querolt, Montse, Camprubí, Sandra, Mondou, Elsa

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  4. 4
    Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo‐controlled trial

    Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double‐blind, placebo... by Bril, Vera, Berkowicz, Tomasz, Szczudlik, Andrzej, Nicolle, Michael W., Bednarik, Josef, Hon, Petr, Vaitkus, Antanas, Vu, Tuan, Rozsa, Csilla, Magnus, Tim, Panczel, Gyula, Toomsoo, Toomas, Pasnoor, Mamatha, Mozaffar, Tahseen, Freimer, Miriam, Reuner, Ulrike, Vécsei, László, Souayah, Nizar, Levine, Todd, Pascuzzi, Robert M., Dalakas, Marinos C., Rivner, Michael, Griffin, Rhonda, Coll, Montse Querolt, Mondou, Elsa

    Published in Muscle & nerve
    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  5. 5
    Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primary immunodeficiency (PI)

    Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) has a positive safety and tolerability profile in an open-label, multicenter, phase 3 study in primar... by Wedner, H. James, Sleasman, John, Lumry, William, Hussain, Iftikhar, Harris, James, Mondou, Elsa, Lin, Jiang, Hames, Carrie, Querolt, Montse, Stein, Mark

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

    Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multic... by Sleasman, John, Lumry, William, Hussain, Iftikhar, Wedner, H. James, Harris, James, Mondou, Elsa, Lin, Jiang, Hames, Carrie, Querolt, Montse, Stein, Mark

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: